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Rate of Synthesis of Coagulation Factors IIr VIIr IX, anil X
During Substitution Therapy with P.P. S.B.
E.A.Loer,rcBn; A.HrNsnN; M.J.MarrxnN and H.C.Hrr''trrn (Leyden, The Nethedands)
P.P.S.B., which I had been told by Dt. Sour,rrn is now commetcially available in
suff,cient amounts to be used on a large scale, appeated most suitable and con-
venient for the treatment of haemophilia B [r, z]. Shortages of factors II, VII, and
X, with the exception of acquited factor Il-deficiency in lupus erythematosus and
acquired factor X-deficiency in amyloidosis, should also respond well to P.P.S.B.
Plasma levels of coagulation factofs to be expected from the amount of P.P.S.B.
transfused can be calculated by means of formulas used earlier [r]. It is evident that
the levels obtained in a patient afe pfopoftional to the amount and to the biological
ty" of the coagulation factors transfused. Once equilibrium between infusion rate
and metabolic decay is attained in a patient displaying no production of his own,
the requirement for maintenance of a z5o/o level would, pef kg/houf, amount to the
equivalent of fresh normal plasma for:
Factor Il-deficiency o.z ml
Factot Vll-deficiency 2.4 ml
Factot IX-deficiency o.6 ml
Factor X-deficiency o46 ml
These amounts hold for notmal metabolic conditions, under which the ty2 of fac-
tors II, VII, IX, and X are 7 z, 6, z4 and 4o h respectively.
What we wefe not sute about until fecently, but nevertheless appeared all im-
poftant to know from the point of view of economy of substitution thefapy, was
vrhether the fate of the patient's own synthesis of the coagulation factors under
discussion was altered during substitution. If the rate of synthesis were not altered,
then the level obtained dudng transfusion of P.P.S.B. would be the sum of the
patient's o,il/n level and the level to be expected from the amount transfused. Mild
cases offactors II, VII, IX, and X deficiency, that is to say cases displaying a coa-
gulation factor activity of 5 7o-zoo/, of the missing coagulation factor, v/ould then
requite substantially less P.P.S.B. for the attainment of the safe 2ro/o-3oo/o leYel.
we recently had an opportunity to study a haemophilia B patient belonging to
the mild variety who was operated upon under the protection of P.P.S.B. The prep-
aration was given at a cotrstant infusion tate and the daily amount was equivalent
to about r.; I fresh normal plasma (factorIl :1461, factot VII r.5zl,factotIX o.8 l,
andf^ctot X r.48 1). Pertinent coagulation factof activities in the patient's plasma
wefe measufed twice daity during the whole period of substitution. Equilibrium
between the infusion rzte and r:;te of metabolic decay of the coagulation factofs
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Tabh I
Coagulation factor activity ("7")
calculated measured
Factor II
Factor VII
Factor IX
Factot X
z r 8
84
40
r70
r83
ro3
4t
2 t ,
transfused rfiras supposed to have been attained within the first four days of treat-
ment, the plasma levels assessed between the yth and 9th day being rather constant.
Independence of production rate with respect to plasma levels is sttongly suggested
by the results obtained in this patient: as shown in table I, the plasma levels meas-
ured for factors II, VII, IX, and X appeared to be in teasonable accordance with the
sum of patient's basic levels @asic levels: 960/0, 72o/o, r6yo, and gt % rcsp.) and the
level calculated from the amount transfused (calculated levels: r22yo, r2yo, 24o/o,
and 75 % resp). All figures given in table I are ^ yetage values of 8 observations.
fn conclaion: Our statement, made some years ago, that patients suffering ftom mild
coagulation disorders in case of maior ttauma or major surgery should with respect
to substitution be regarded as sevetely affected, seems likely to be wrong, since
transfusion of.large amounts of factors II, VII, IX, and X into a patient suf[ering
from mild haemophilia B did not diminish the rate of synthesis of these factors.
Hence, adequate substitution, i. e. attaiflment and maintenance of a z7 /o-3oo/olevel,
will be easier to obtain in mild deficiency of factors II, VII, IX, and X than in cases
of severe deficiency of these coagulation factors.
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